Trade Summary

4 months ago, Genmab A/S, serving as 10% owner at Merus N.V. (MRUS), purchased 76,922,983 shares at $1.33 per share, for a total transaction value of $102,411,145.00.

This purchase represents a 100.00% decrease in Genmab A/S's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, December 26, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, December 30, 2025 at 5:41 PM ET, 4 days after the trade was made.

Merus N.V. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.